About 1 in every 526 people in the U.S. will be diagnosed with chronic myeloid leukemia (CML) this year, but most of these people will achieve their normal life expectancy thanks to tyrosine kinase ...

Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...

BEDFORD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative ...

Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to ...

A real-world study demonstrated better survival outcomes when an immunotherapy is combined with a tyrosine kinase inhibitor rather than another immunotherapy therapy for intermediate-risk renal cell ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this Healio Video Perspective from the ASRS meeting, ...

Treatment with a vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFR–TKI) after previous treatment with checkpoint-inhibitor therapy alone or in combination with a VEGFR–TKI ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SALT LAKE CITY — In this Healio Video Perspective from ...

LOUISVILLE, Ky. -- Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started treatment with a targeted drug, results of a small ...